Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B in children: complexities in management.

Nanda Kerkar1

  • 1Division of Pediatric Hepatology and Recanati Miller Transplant Institute, Mount Sinai School of Medicine, New York, NY 10029, USA. nanda.kerkar@msnyuhealth.org

Pediatric Transplantation
|September 24, 2005
PubMed
Summary

Chronic hepatitis B (HBV) infection occurs when hepatitis B surface antigen persists for over six months. Current therapies aim to suppress HBV replication and prevent liver disease progression, with future treatments focusing on restoring T-cell responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Condition-Specific Growth Charts for Children With Alagille Syndrome.

JAMA network open·2025
Same author

Autoimmune hepatitis in children: Guidelines of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN).

Hepatology international·2025
Same author

Elevated Serum Bile Acids Predict Poor Liver Outcomes in Children With Alagille Syndrome: Results From the GALA Study Group.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Phenotypic Divergence of JAG1- and NOTCH2-Associated Alagille Syndrome & Disease-Specific NOTCH2 Variant Classification Guidelines.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

The Society of Pediatric Liver Transplantation (SPLIT): 2023 Registry Status.

Pediatric transplantation·2025
Same author

Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B virus (HBV) infection is defined by persistent hepatitis B surface antigen (HBsAg) for over six months.
  • Risk of chronicity is high in neonates (90%) but low (<5%) in immunocompetent adults.
  • Perinatal HBV infection often presents with an immune-tolerant phase (high HBV-DNA, HBeAg, normal ALT).

Purpose of the Study:

  • To review current therapeutic goals and strategies for chronic HBV infection.
  • To discuss licensed treatments for adults and children, including interferon-alpha (IFN-alpha) and nucleoside analogues.
  • To highlight future directions in HBV treatment, focusing on immune restoration.

Main Methods:

  • Review of existing literature on chronic hepatitis B diagnosis, pathogenesis, and treatment.

Related Experiment Videos

  • Comparison of licensed therapies: interferon-alpha (IFN-alpha) and nucleoside analogues (lamivudine, adefovir dipivoxil).
  • Discussion of treatment considerations for specific populations, including children and liver transplant recipients.

    • Main Results:

    • Chronic HBV infection is characterized by T-cell hyporesponsiveness.
    • Licensed drugs (IFN-alpha, LMV, ADV) aim to suppress viral replication and prevent liver disease progression (cirrhosis, HCC).
    • Nucleoside analogues are suitable for decompensated cirrhosis and transplant recipients; newer drugs can manage LMV-resistant mutants.

    Conclusions:

    • Therapeutic goals include HBV replication suppression and prevention of liver disease progression.
    • IFN-alpha offers durable responses but has disadvantages; nucleoside analogues are orally available and versatile.
    • Future HBV therapies should aim to restore HBV-specific T-cell responses for effective viral control.